Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flortanidazole F 18

Drug Profile

Flortanidazole F 18

Alternative Names: 18F-flortanidazole; [18F]-HX4; Flortinidazole (18F)

Latest Information Update: 31 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Siemens AG
  • Developer Maastricht University; Siemens AG; Threshold Pharmaceuticals
  • Class Nitroimidazoles; Radiopharmaceutical diagnostics; Small molecules; Triazoles
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 29 Jun 2017 Flortanidazole F 18 is available for licensing as of 29 Jun 2017. http://www.thresholdpharm.com/overview-1/
  • 27 Mar 2017 Discontinued - Phase-I for Solid tumours (Diagnosis) in Netherlands (Parenteral)
  • 27 Mar 2017 Discontinued - Phase-II for Head and neck cancer (Diagnosis, Metastatic disease, Recurrent) in Australia and USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top